Drug intelligence / Profile preview

RJV-117

Development stage: Preclinical
Lead developer: Rejenevie Therapeutics
Modality: Cell Therapies

Overview

RJV-117 is a **preclinical cell therapy program** from **Rejenevie Therapeutics** designed for **immune restoration**. The product is described as a combination of **factors isolated from young blood stem and immune cells**, derived from the company's parabiosis-inspired platform and proprietary Transwell discovery system that identifies restorative signals released by young hematopoietic and immune cells. Rejenevie positions RJV-117 for broad use across **all Okyanos treating indications**, with proposed applications in **oncology including liquid tumors and solid tumors**, as well as **infectious disease**. No discrete molecular target has been publicly specified.

Beyond the preview

Go deeper on RJV-117.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJV-117.

Explore the full profile